Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Goldenwell Biotech, Inc. (GWLL)
Hudson, OH, US
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -9.56% | -10.01% | -14.30% | -70.00% | -68.97% | +349.95% | +1,435.67% | +205.05% | +205.05% | +205.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Pharmaceuticals: +7.8%-94.1%
-
EPS growth Medical - Pharmaceuticals: +20.2%-8.3% Q3'25: +50.0% (vs Q3'24)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-94,587.8% Q3'25: -123.5% (vs Q3'24)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-88,559.7% Q3'25: -23.5% (vs Q3'24)
-
ROIC Medical - Pharmaceuticals: +6.1%— Q3'25: +16.8% (vs Q3'24)
-
Share dilution Medical - Pharmaceuticals: +0.0%+2.7% Q3'25: +0.0% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.78× Q3'25: 0.00× (vs Q3'24)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Shuang Liu | 41.00M | 41.40% | 41.00M | — | 41.00M | — | IN | China | 2023-05-23 | ↗ |
| 2 | Li Yang | 10.00M | 10.10% | 10.00M | — | 10.00M | — | IN | Australia | 2023-05-23 | ↗ |
| 3 | (. James Wang | 7.00M | 7.00% | 7.00M | — | 7.00M | — | IN | United States | 2023-10-10 | ↗ |
| 4 | Hua Xie | 5.00M | 5.00% | 5.00M | — | 5.00M | — | IN | United States | 2023-05-23 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hua Xie | Secretary & Director | — | female |
| Li Yang | Treasurer & Director | — | male |
| Shuang Liu | Chairman, Chief Executive Officer & President | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GWLL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
